Geneve, Geneva, Switzerland The main office of represented Corporate Investor is situated in the Geneva. The venture was found in Europe in Switzerland.
The fund is constantly included in less than 2 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2018.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the General Oriental, startups are often financed by Carebridge Holdings, Apricot Capital. The meaningful sponsors for the fund in investment in the same round are Trustbridge Partners, GP Healthcare Capital.
For fund there is no match between the location of its establishment and the land of its numerous investments - China. Among the most successful fund investment fields, there is Biotechnology. Among the most popular portfolio startups of the fund, we may highlight GenomiCare Biotechnology. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Candela Paramount | - |
| Decathlon Capital Partners | California, Palo Alto, United States |
| DS Capital Partners | Mexico, Nuevo León, Nuevo Leon |
| EndoLogic USA | - |
| Fox Corporation | New York, New York, United States |
| French sovereign investment bank | - |
| GEEK PICTURES | Japan, Tokyo |
| GETTYLAB | California, San Francisco, United States |
| Lafayette Group | United States, Vienna, Virginia |
| Properties | Chicago, Illinois, United States |
| Sampension | Denmark, Hellerup, Hovedstaden |
| SM Ventures | New York, New York, United States |
| South Central Ventures | Belgrade, Serbia, Vojvodina |
| State National Companies | Bedford, Texas, United States |
| Suzhou Botao Chuang tou | China, Jiangsu, Suzhou |
| Teck | British Columbia, Canada, Vancouver |
| The New Republic Fund | District of Columbia, United States, Washington |
| Tongdao Chuangye | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
GenomiCare Biotechnology | $30M | 18 Dec 2018 | Shanghai |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
GenomiCare Biotechnology | $30M | 18 Dec 2018 | Shanghai |
